Clinical Trials Browser

Phase 2 × Breast Neoplasms × glembatumumab vedotin × Clear all

NCT01997333 2019-03-08

METRIC

Phase 2 Completed

327 enrolled 17 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01156753 2017-07-02

EMERGE

Phase 2 Completed

Breast Neoplasms